Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?

Research output: Contribution to journalReviewResearchpeer-review

  1. Diabetes and the Risk of Sudden Cardiac Death

    Research output: Contribution to journalReviewResearchpeer-review

  2. Does Left Atrial Appendage Amputation During Routine Cardiac Surgery Reduce Future Atrial Fibrillation and Stroke?

    Research output: Contribution to journalReviewResearchpeer-review

  3. Functional Information in Coronary Artery Disease: The Case of Computed Tomography Myocardial Perfusion

    Research output: Contribution to journalReviewResearchpeer-review

  4. Off-pump versus on-pump coronary artery bypass grafting

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Pharmacogenomics and cardiovascular disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cardiac chamber volumes and left ventricular mass in people living with HIV and matched uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE OF REVIEW: To summarize and discuss the clinical use of lipid and apolipoprotein tests in the settings of diagnosis and therapeutic follow-up of hyperlipidemia.

RECENT FINDINGS: The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently produced recommendations on the measurement of atherogenic lipoproteins, taking into account the strengths and weaknesses of analytical and clinical performances of the tests. Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and calculated non-HDL cholesterol (= LDL + remnant cholesterol) constitute the primary lipid panel for hyperlipidemia diagnosis and cardiovascular risk estimation. LDL cholesterol is the primary target of lipid-lowering therapies. Non-HDL cholesterol or apolipoprotein B should be used as secondary therapeutic target in patients with mild-to-moderate hypertriglyceridemia, 2-10 mmol/l (175-880 mg/dl). Lipoprotein (a) is included in LDL cholesterol and should be measured at least once in all patients at cardiovascular risk, including to explain poor response to statin treatment.

Original languageEnglish
JournalCurrent Cardiology Reports
Volume20
Issue number10
Pages (from-to)88
ISSN1534-3170
DOIs
Publication statusPublished - 17 Aug 2018

ID: 56621711